Atopic Dermatitis
Conditions
Interventions
Dupixent :Dupixent (dupilumab) (Sanofi/, France) for adults: an initial dose of 600 mg, followed by 300 mg every two weeks via subcutaneous injection
for children weighing between 15 kg and 30 kg, a single 300 mg injection every four weeks after the initial dose.
Upadacitinib:The therapeutic dose should be adjusted based on the patient’s condition and treatment response. The starting dose is 15 mg once daily, which can be increased to 30 mg once daily if neces
Sponsors
The Fourth Affiliated Hospital of Soochow University (Suzhou Dushuhu Hospital)
Eligibility
Sex/Gender
All
Age
12 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1 Age >= 12 years, body weight >= 40 kg, gender not limited; 2 Meets the diagnostic criteria for moderate-to-severe atopic dermatitis according to the Williams scoring standard; 3 Capable of understanding and voluntarily signing a written informed consent form, able to complete treatment and follow-up as required.
Exclusion criteria
Exclusion criteria: 1 Pregnant or breastfeeding; 2 Received systemic treatment (including phototherapy, systemic corticosteroids, immunosuppressants, 3 etc.) within 6 months before the first treatment; 3 Systemic diseases, such as malignant tumors, severe infections, immunodeficiency disorders, impaired liver or kidney function, diabetes, lupus, etc.; 4 Neurological or psychiatric disorders. 5 During the study, patients were informed not to use any other treatment methods specifically for atopic dermatitis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| EASI;SCORAD;DLQI;SAS;SAS;Skin moisture test;Sebum test;TEWL;Allergen testing;IgE;Epidermal RNA Metabolomics;Epidermal Lipidomics; | — |
Secondary
| Measure | Time frame |
|---|---|
| Likert satisfactions; | — |
Countries
China
Contacts
Public Contactmin li
The Fourth Affiliated Hospital of Soochow University
Outcome results
None listed